AIM
IOVA icon

Artemis Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Artemis Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-58,893
Closed -$1.45M – 290
2021
Q3 		$1.45M Sell
58,893
-569
-1% -$13.4K 0.01% 270
2021
Q2 		$1.55M Buy
+59,462
New +$1.55M 0.01% 254

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artemis Investment Management's IOVA Position: Q4 2021 in Review

Artemis Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 58,893 shares — an estimated $1.45M sold.

Artemis Investment Management first reported a position in IOVA in Q2 2021 and held it in 2 quarters. The position peaked at $1.55M in Q2 2021. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

  • Artemis Investment Management reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Artemis Investment Management sold 58,893 Iovance Biotherapeutics shares in Q4 2021, an estimated $1.45M.
  • Artemis Investment Management first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Artemis Investment Management's Iovance Biotherapeutics position peaked at $1.55M in Q2 2021.
  • 246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on Artemis Investment Management's 13F filing for Q4 2021, filed 8 Feb 2022.